Results 31 to 40 of about 20,344 (273)

Sclerostin inhibition alleviates breast cancer-induced bone metastases and muscle weakness [PDF]

, 2019
Breast cancer bone metastases often cause a debilitating non-curable condition with osteolytic lesions, muscle weakness and a high mortality. Current treatment comprises chemotherapy, irradiation, surgery and anti-resorptive drugs that restrict but do ...
Brandt, Diana, Hesse, Eric, Pamperin, Jenny, Saito, Hiroaki, Schröder, Saskia, Taipaleenmäki, Hanna   +5 more
core   +1 more source

Drug discovery of sclerostin inhibitors

Acta Pharmaceutica Sinica B, 2022
Sclerostin, a protein secreted from osteocytes, negatively regulates the WNT signaling pathway by binding to the LRP5/6 co-receptors and further inhibits bone formation and promotes bone resorption. Sclerostin contributes to musculoskeletal system-related diseases, making it a promising therapeutic target for the treatment of WNT-related bone diseases.
Sifan Yu, Dijie Li, Ning Zhang, Shuaijian Ni, Meiheng Sun, Luyao Wang, Huan Xiao, Dingdong Liu, Jin Liu, Yuanyuan Yu, Zongkang Zhang, Samuel Tin Yui Yeung, Shu Zhang, Aiping Lu, Zhenlin Zhang, Baoting Zhang, Ge Zhang   +16 more
openaire   +3 more sources

Sclerostin is a promising therapeutic target for oral inflammation and regenerative dentistry

Journal of Translational Medicine, 2022
Sclerostin is the protein product of the SOST gene and is known for its inhibitory effects on bone formation. The monoclonal antibody against sclerostin has been approved as a novel treatment method for osteoporosis.
Chufang Liao, Shanshan Liang, Yining Wang, Ting Zhong, Xiangning Liu   +4 more
doaj   +1 more source

Wnt signaling pathway inhibitors, sclerostin and DKK-1, correlate with pain and bone pathology in patients with Gaucher disease

Frontiers in Endocrinology, 2022
Patients with Gaucher disease (GD) have progressive bone involvement that clinically presents with debilitating bone pain, structural bone changes, bone marrow infiltration (BMI), Erlenmeyer (EM) flask deformity, and osteoporosis. Pain is referred by the
Margarita M. Ivanova, Julia Dao, Neil Kasaci, Andrew Friedman, Lauren Noll, Ozlem Goker-Alpan   +5 more
doaj   +1 more source

Transient peak-strain matching partially recovers the age-impaired mechanoadaptive cortical bone response [PDF]

, 2018
Mechanoadaptation maintains bone mass and architecture; its failure underlies age-related decline in bone strength. It is unclear whether this is due to failure of osteocytes to sense strain, osteoblasts to form bone or insufficient mechanical stimulus ...
A Carriero, A Moustafa, AF Pereira, AG Robling, AG Robling, AH Ng, AI Birkhold, AI Birkhold, AM Hanson, AM Weatherholt, B Javaheri, B Javaheri, B Javaheri, B Javaheri, B Kamal, BM Willie, C Liu, C Turner, CA Schneider, CH Turner, CT Rubin, DB Burr, DB Burr, DM Cullen, E Smith, ER Spector, EW Helge, F Bini, G Ducher, H Razi, J Wergedal, JR Mosley, JR Mosley, K Deere, K Deere, KC Lee, KE Poole, KJ Jepsen, LB Meakin, LE Lanyon, LE Lanyon, LE Lanyon, LE Lanyon, M Doube, M Schaffler, M Steiner, MD Brodt, MD Willinghamm, ME Lynch, MM Shimano, N Holguin, N Holguin, N Holguin, N Lara-Castillo, P Lind, P Sztefek, R DeSouza, RH Routh, RL Souza De, SM Millard, SM Ponik, T Jämsä, TC Lee, TK Patel, Y Umemura   +64 more
core   +4 more sources

Endocrine functions of sclerostin

Current Opinion in Endocrine and Metabolic Research, 2023
Sclerostin, the product of the SOST gene has primarily been studied for its profound impact on bone mass. By interacting with LRP5 and LRP6, the glycoprotein suppresses the propagation of Wnt signals to β-catenin and thereby suppresses new bone formation.
openaire   +2 more sources

Association of sclerostin with cardiovascular events and mortality in dialysis patients

Renal Failure, 2020
Introduction Sclerostin has been reported to be a novel biomarker associated with the bone-vascular axis. In this study, we determined the relationships between serum sclerostin and all-cause mortality, the prevalence of cardiovascular events (CVEs), and
Yun Zou, Min Yang, Jiao Wang, Li Cui, Zhenxing Jiang, Jiule Ding, Min Li, Hua Zhou   +7 more
doaj   +1 more source

Identification of Sclerostin as a Putative New Myokine Involved in the Muscle-to-Bone Crosstalk

Biomedicines, 2021
Bone and muscle have been recognized as endocrine organs since they produce and secrete “hormone-like factors” that can mutually influence each other and other tissues, giving rise to a “bone–muscle crosstalk”.
Maria Sara Magarò, Jessika Bertacchini, Francesca Florio, Manuela Zavatti, Francesco Potì, Francesco Cavani, Emanuela Amore, Ilaria De Santis, Alessandro Bevilacqua, Luca Reggiani Bonetti, Pietro Torricelli, Delphine B. Maurel, Stefano Biressi, Carla Palumbo   +13 more
doaj   +1 more source

The sclerostin-bone protein interactome [PDF]

Biochemical and Biophysical Research Communications, 2012
The secreted glycoprotein, sclerostin alters bone formation. To gain insights into the mechanism of action of sclerostin, we examined the interactions of sclerostin with bone proteins using a sclerostin affinity capture technique. Proteins from decalcified rat bone were captured on a sclerostin-maltose binding protein (MBP) amylose column, or on a MBP ...
Hemamalini, Devarajan-Ketha, Theodore A, Craig, Benjamin J, Madden, H, Robert Bergen, Rajiv, Kumar   +4 more
openaire   +2 more sources

Assessment of sclerostin levels in the gingival crevicular fluid of patients with periodontitis: A clinico-biochemical crosssectional study [PDF]

Journal of Advanced Periodontology and Implant Dentistry, 2023
Background. Sclerostin, a glycoprotein, plays a key role in regulating bone mass. In this study, sclerostin levels in the gingival crevicular fluid (GCF) were assessed in patients with Stage III Grade C generalized periodontitis (SIII-GC) and Stage III ...
Nisha Ashifa, Krishnan Viswanathan, Sivapragasam Srinivasan, Senthil Kumar, Rajasekar Sundaram, Varsha K. Pavithran   +5 more
doaj   +1 more source